tradingkey.logo

AIM ImmunoTech Inc

AIM
查看詳細走勢圖
0.557USD
-0.134-19.38%
收盤 03/30, 16:00美東報價延遲15分鐘
143.42K總市值
虧損本益比TTM

AIM ImmunoTech Inc

0.557
-0.134-19.38%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-19.38%

5天

-41.86%

1月

-27.83%

6月

-79.65%

今年開始到現在

-50.61%

1年

0.00%

查看詳細走勢圖

TradingKey AIM ImmunoTech Inc股票評分

單位: USD 更新時間: 2026-03-27

操作建議

AIM ImmunoTech Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名115/391位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為21.98。中期看,股價處於下降通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

AIM ImmunoTech Inc評分

相關信息

行業排名
115 / 391
全市場排名
231 / 4542
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

AIM ImmunoTech Inc亮點

亮點風險
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
業績增長期
公司處於發展階段,最新年度總收入88.00K美元
估值合理
公司最新PE估值-0.08,處於3年歷史合理位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉17.52K股

分析師目標

基於 1 分析師
買入
評級
21.978
目標均價
+3078.31%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

AIM ImmunoTech Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

AIM ImmunoTech Inc簡介

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
公司代碼AIM
公司AIM ImmunoTech Inc
CEOEquels (Thomas K)
網址https://aimimmuno.com/
KeyAI